Date: 2013-07-29
Type of information: Grant
Company: Arecor (UK)
Investors:
Amount:
Funding type: award
Planned used: The funds will be used to develop a stable formulation for the flu vaccine candidate REDEE FLU™.
Others: * On July 29, 2013, Arecor has received the funding to pursue a research project applying Arecor’s innovative Arestat™ formulation technology to a promising flu vaccine, REDEE FLU™, developed by the US company FluGen. The UK’s innovation agency, the Technology Strategy Board, has awarded Arecor a Proof of Concept award through its Smart programme, to engage in research and development in the strategically important area of developing a stable formulation for REDEE FLU™.
A critical component to the success of REDEE FLU™ is how it is formulated for storage and shipment. This is where the innovative UK formulation experts Arecor join the team. The Arecor/FluGen international collaboration will begin in July and continue into 2014.
Therapeutic area: Infectious diseases
